BioClinica Launches New IVR/IWR Platform, Trident IWR
BioClinica, Inc. announced the launch of its new IVR/IWR (interactive voice response/interactive web response) platform, Trident IWR, at the 2010 Society for Clinical Data Management Annual Conference (SCDM). Trident IWR’s interface provides clinical operations personnel with an intuitive and faster way to directly set up, monitor, and maintain randomization and supplies for their clinical trials.
“We believe that Trident will fundamentally change the IVR/IWR market. Trident gives customers the ability to build complex trials in a quicker and less costly manner than previous alternatives which require the development of custom programming for each new clinical trial,” said Mark Weinstein, CEO of BioClinica.
Designed from inception as a web-based system, Trident simultaneously delivers IVR phone support through the same simplified configuration process. It is fully synchronized with BioClinica Optimizer a clinical supply simulation and visualization package. Study designs simulated in Optimizer can configure Trident IWR to precisely match the optimal scenario identified using Optimizer. After deployment, Trident data can update Optimizer, and then Optimizer can re-simulate and reforecast. BioClinica will conduct educational Trident-related webinars beginning in November 2010. For more information about these sessions please visit: http://www.bioclinica.com/webinars/.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.
